Transarterial chemoembolization combined with lenvatinib vs transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Table 1 Basic characteristics and quality assessment of included studies

Ref.	Country	Period	Medical center	Study type	TACE + LEN vs TACE + SOR, n	Gender (F/M), TACE + LEN	Gender (F/M), TACE + SOR	Age, TACE + LEN	Age, TACE + SOR	Quality
Ding et al[15], 2021	China	2018-2020	Beijing Ditan Hospital	R	32 vs 32	7/25	5/27	57 ± 11	56 ± 11	5
Xue et al[16], 2021	China	2017-2020	First Affiliated Hospital of Sun Yat-Sen University	RCT	50 vs 100	4/46	3/97	54 (49-61)	54 (49-63)	6
Xu et al[17], 2023	China	2019-2021	First Affiliated Hospital of Anhui Medical University	R	43 vs 41	18/25	17/24	55 ± 12.26	52.5 ± 11.47	6
Yang et al[18], 2021	China	2017-2020	West China Medical School	R	38 vs 38	4/34	4/34	55.18 ± 10.94	54.39 ± 12.17	NA
Zhang et al[19], 2022	China	2018-2021	The First Affiliated Hospital with Nanjing Medical University	R	53 vs 59	9/44	7/52	57.7 ± 11.8	58.8 ± 11.1	7
Zhao et al[20], 2022	China	2018-2020	Chinese People’s Liberation Army General Hospital, Beijing	R	32 vs 29	1/31	4/25	57.38 ± 9.44	55.90 ± 8.18	7

R: Retrospective cohort studies; RCT: Randomized controlled trial; M: Male; F: Female; TACE: Transarterial chemoembolization; LEN: Lenvatinib; SOR: Sorafenib; NA: Not available.